CoChat
Sign Up
Cited by 2,612

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

McDonagh, Theresa A, Metra, Marco, Adamo, Marianna, Gardner, Roy S, Baumbach, Andreas, Böhm, Michael, Burri, Haran, Butler, Javed, Čelutkienė, Jelena, Chioncel, Ovidiu, Cleland, John G F, Crespo-Leiro, Maria Generosa, Farmakis, Dimitrios, Gilard, Martine, Heymans, Stephane, Hoes, Arno W, Jaarsma, Tiny, Jankowska, Ewa A, Lainscak, Mitja, Lam, Carolyn S P, Lyon, Alexander R, McMurray, John J V, Mebazaa, Alexandre, Mindham, Richard, Muneretto, Claudio, Francesco Piepoli, Massimo, Price, Susanna, Rosano, Giuseppe M C, Ruschitzka, Frank, Skibelund, Anne Kathrine, ESC Scientific Document Group, de Boer, Rudolf A, Schulze, P Christian, Arbelo, Elena, Bartunek, Jozef, Bauersachs, Johann, Borger, Michael A, Buccheri, Sergio, Cerbai, Elisabetta, Donal, Erwan, Edelmann, Frank, Färber, Gloria, Heidecker, Bettina, Ibanez, Borja, James, Stefan, Køber, Lars, Koskinas, Konstantinos C, Masip, Josep, McEvoy, John William, Mentz, Robert, Mihaylova, Borislava, Møller, Jacob Eifer, Mullens, Wilfried, Neubeck, Lis, Nielsen, Jens Cosedis, Pasquet, Agnes A, Ponikowski, Piotr, Prescott, Eva, Rakisheva, Amina, Rocca, Bianca, Rossello, Xavier, Sade, Leyla Elif, Schaubroeck, Hannah, Tessitore, Elena, Tokmakova, Mariya, van der Meer, Peter, Van Gelder, Isabelle C, Van Heetvelde, Mattias, Vrints, Christiaan, Wilhelm, Matthias, Witkowski, Adam, Zeppenfeld, Katja, Shuka, Naltin, Chettibi, Mohammed, Hayrapetyan, Hamlet, Pavo, Noemi, Islamli, Aysel, Pouleur, Anne-Catherine, Kusljugic, Zumreta, Tokmakova, Mariya, Milicic, Davor, Christodoulides, Theodoros, Malek, Filip, Køber, Lars, Koriem, Mohamed Abdel Ghany, Põder, Pentti, Lassus, Johan, Roubille, François, Agladze, Vaja, Frantz, Stefan, Stavrati, Alexia, Kosztin, Annamaria, Ingimarsdóttir, Inga Jóna, Campbell, Patricia, Hasin, Tal, Oliva, Fabrizio, Aidargaliyeva, Nazipa, Bajraktari, Gani, Mirrakhimov, Erkin, Kamzola, Ginta, El Neihoum, Ali M, Zaliaduonyte, Diana, Moore, Alice, Vataman, Eleonora, Boskovic, Aneta, Alami, Mohamed, Manintveld, Olivier, Kostovska, Elizabeta Srbinovska, Broch, Kaspar, Nessler, Jadwiga, Franco, Fatima, Popescu, Bogdan A, Foscoli, Marina, Milosavljevic, Anastazija Stojsic, Goncalvesova, Eva, Fras, Zlatko, Gonzalez-Costello, Jose, Lindmark, Krister, Paul, Matthias, Oudeh, Abdulnasser, Zakhama, Lilia, Celik, Ahmet, Voronkov, Leonid, Clark, Andrew, Abdullaev, Timur, Prescott, Eva, James, Stefan, Arbelo, Elena, Baigent, Colin, Borger, Michael A, Buccheri, Sergio, Ibanez, Borja, Køber, Lars, Koskinas, Konstantinos C, McEvoy, John William, Mihaylova, Borislava, Mindham, Richard, Neubeck, Lis, Nielsen, Jens Cosedis, Pasquet, Agnes A, Rakisheva, Amina, Rocca, Bianca, Rossello, Xavier, Vaartjes, Ilonca, Vrints, Christiaan, Witkowski, Adam, Zeppenfeld, Katja·2023·European Heart Journal
DOI 10.1093/eurheartj/ehad195
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehad195

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The findings were first benchmarked against results from the STEP-HFpEF DM and SUMMIT trials.

    “these findings were first benchmarked against results from the STEP-HFpEF DM and SUMMIT trials.9-11,55”

    From Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction (2025) · cites this paper as [9]

    The Chronic heart failure section discusses results from EMPEROR-Preserved and DELIVER, but does not describe benchmarking findings against STEP-HFpEF DM or SUMMIT. Searches of our full-text copy for both trial names and for the proposed benchmarking found no passage addressing it; the paper’s discussion of other trials does not establish that the benchmarking occurred. (LLM, conf=0.76)

    Experimental — accuracy not yet measured

  • Guideline committees withheld formal recommendations for semaglutide and tirzepatide in HFpEF pending confirmation of benefits on clinical outcomes.

    “Similarly, guideline committees withheld formal recommendations pending confirmation of benefits on clinic al outcomes to complement these trial findings.9-12”

    From Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction (2025) · cites this paper as [9]

    Section 3 (Chronic heart failure; page unavailable) discusses recommendations for other HFpEF therapies, including SGLT2 inhibitors, but does not address withholding recommendations for semaglutide or tirzepatide pending clinical-outcome evidence. Searches for both drug names and related recommendation language found no passage addressing that claim. (LLM, conf=0.76)

    Experimental — accuracy not yet measured

  • Regulatory agencies and guideline committees have emphasized the need for further evidence for major clinical outcomes in heart failure.

    “Because regulatory agencies and guideline committees have emphasized the need for further evidence for major clinical outcomes in heart failure”

    From Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction (2025) · cites this paper as [9]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 35

  1. McDonagh, 2021, 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure, Eur Heart J, 42, 3599, 10.1093/eurheartj/ehab368 · DOI · Paper page
  2. Mullens, 2022, Acetazolamide in acute decompensated heart failure with volume overload, N Engl J Med, 387, 1185, 10.1056/NEJMoa2203094 · DOI
  3. Trullàs, 2023, Combining loop with thiazide diuretics for decompensated heart failure: the CLOROTIC trial, Eur Heart J, 44, 411, 10.1093/eurheartj/ehac689 · DOI
  4. Lee, 2023, Trial of an intervention to improve acute heart failure outcomes, N Engl J Med, 388, 22, 10.1056/NEJMoa2211680 · DOI
  5. Voors, 2022, The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial, Nat Med, 28, 568, 10.1038/s41591-021-01659-1 · DOI · Paper page
  6. Kalra, 2022, Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial, Lancet, 400, 2199, 10.1016/S0140-6736(22)02083-9 · DOI
  7. Macdougall, 2019, Intravenous iron in patients undergoing maintenance hemodialysis, N Engl J Med, 380, 447, 10.1056/NEJMoa1810742 · DOI
  8. Jhund, 2021, Heart failure hospitalization in adults receiving hemodialysis and the effect of intravenous iron therapy, JACC Heart Fail, 9, 518, 10.1016/j.jchf.2021.04.005 · DOI
  9. Perera, 2022, Percutaneous revascularization for ischemic left ventricular dysfunction, N Engl J Med, 387, 1351, 10.1056/NEJMoa2206606 · DOI
  10. Mentz, 2023, Effect of torsemide vs furosemide after discharge on all-cause mortality in patients hospitalized with heart failure: the TRANSFORM-HF randomized clinical trial, JAMA, 329, 214, 10.1001/jama.2022.23924 · DOI
  11. Sorajja, 2023, Transcatheter repair for patients with tricuspid regurgitation, N Engl J Med, 388, 1833, 10.1056/NEJMoa2300525 · DOI
  12. Anker, 2020, Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial, Eur J Heart Fail, 22, 2383, 10.1002/ejhf.2064 · DOI
  13. Solomon, 2021, Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial, Eur J Heart Fail, 23, 1217, 10.1002/ejhf.2249 · DOI
  14. Solomon, 2022, Baseline characteristics of patients with HF with mildly reduced and preserved ejection fraction: DELIVER trial, JACC Heart Fail, 10, 184, 10.1016/j.jchf.2021.11.006 · DOI
  15. Vardeny, 2022, Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial, Nat Med, 28, 2504, 10.1038/s41591-022-02102-9 · DOI
  16. Jhund, 2022, Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER, Nat Med, 28, 1956, 10.1038/s41591-022-01971-4 · DOI
  17. Masip, 2022, Acute Heart Failure in the 2021 ESC Heart Failure Guidelines: a scientific statement from the Association for Acute CardioVascular Care (ACVC) of the European Society of Cardiology, Eur Heart J Acute Cardiovasc Care, 11, 173
  18. Cunningham, 2022, Dapagliflozin in patients recently hospitalized with heart failure and mildly reduced or preserved ejection fraction, J Am Coll Cardiol, 80, 1302, 10.1016/j.jacc.2022.07.021 · DOI
  19. Tomasoni, 2022, Sodium–glucose co-transporter 2 inhibitors as an early, first-line therapy in patients with heart failure and reduced ejection fraction, Eur J Heart Fail, 24, 431, 10.1002/ejhf.2397 · DOI
  20. Liu, 2020, Sodium-glucose co-transporter-2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials, Diabetes Obes Metab, 22, 1619, 10.1111/dom.14075 · DOI
  21. Fonarow, 2010, Improving evidence-based care for heart failure in outpatient cardiology practices: primary results of the registry to improve the use of evidence-based heart failure therapies in the outpatient setting (IMPROVE HF), Circulation, 122, 585, 10.1161/CIRCULATIONAHA.109.934471 · DOI
  22. Gheorghiade, 2012, Medication dosing in outpatients with heart failure after implementation of a practice-based performance improvement intervention: findings from IMPROVE HF, Congest Heart Fail, 18, 9, 10.1111/j.1751-7133.2011.00250.x · DOI
  23. Greene, 2018, Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry, J Am Coll Cardiol, 72, 351, 10.1016/j.jacc.2018.04.070 · DOI
  24. Ouwerkerk, 2017, Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study, Eur Heart J, 38, 1883, 10.1093/eurheartj/ehx026 · DOI
  25. Filippatos, 2022, Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO-DKD trial, Eur J Heart Fail, 24, 996, 10.1002/ejhf.2469 · DOI
  26. House, 2019, Heart failure in chronic kidney disease: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference, Kidney Int, 95, 1304, 10.1016/j.kint.2019.02.022 · DOI
  27. Bhatt, 2021, Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease, N Engl J Med, 384, 129, 10.1056/NEJMoa2030186 · DOI · Paper page
  28. Ponikowski, 2020, Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial, Lancet, 396, 1895, 10.1016/S0140-6736(20)32339-4 · DOI
  29. Pocock, 2021, Primary and secondary outcome reporting in randomized trials: JACC state-of-the-art review, J Am Coll Cardiol, 78, 827, 10.1016/j.jacc.2021.06.024 · DOI
  30. Salah, 2023, Intravenous iron infusion in patients with heart failure: a systematic review and study-level meta-analysis, ESC Heart Fail, 10, 1473, 10.1002/ehf2.14310 · DOI
  31. Graham, 2023, Intravenous iron in patients with heart failure and iron deficiency: an updated meta-analysis, Eur J Heart Fail, 25, 528, 10.1002/ejhf.2810 · DOI
  32. Vukadinovic, 2023, Efficacy and safety of intravenous iron repletion in patients with heart failure: a systematic review and meta-analysis, Clin Res Cardiol, 112, 954, 10.1007/s00392-023-02207-2 · DOI
  33. Anker, 2023, Effect of intravenous iron replacement on recurrent heart failure hospitalizations and cardiovascular mortality in patients with heart failure and iron deficiency: a Bayesian meta-analysis, Eur J Heart Fail, 10.1002/ejhf.2860 · DOI
  34. Comin-Colet, 2013, The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: a subanalysis of the FAIR-HF study, Eur Heart J, 34, 30, 10.1093/eurheartj/ehr504 · DOI
  35. Ponikowski, 2015, Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency, Eur Heart J, 36, 657, 10.1093/eurheartj/ehu385 · DOI

Cited by

Sorted by citations

Metadata

Authors
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., Cleland, J. G. F., Crespo-Leiro, M. G., Farmakis, D., Gilard, M., Heymans, S., Hoes, A. W., Jaarsma, T., Jankowska, E. A., Lainscak, M., Lam, C. S. P., Lyon, A. R., McMurray, J. J. V., Mebazaa, A., Mindham, R., Muneretto, C., Francesco Piepoli, M., Price, S., Rosano, G. M. C., Ruschitzka, F., Skibelund, A. K., ESC Scientific Document Group, de Boer, R. A., Schulze, P. C., Arbelo, E., Bartunek, J., Bauersachs, J., Borger, M. A., Buccheri, S., Cerbai, E., Donal, E., Edelmann, F., Färber, G., Heidecker, B., Ibanez, B., James, S., Køber, L., Koskinas, K. C., Masip, J., McEvoy, J. W., Mentz, R., Mihaylova, B., Møller, J. E., Mullens, W., Neubeck, L., Nielsen, J. C., Pasquet, A. A., Ponikowski, P., Prescott, E., Rakisheva, A., Rocca, B., Rossello, X., Sade, L. E., Schaubroeck, H., Tessitore, E., Tokmakova, M., van der Meer, P., Van Gelder, I. C., Van Heetvelde, M., Vrints, C., Wilhelm, M., Witkowski, A., Zeppenfeld, K., Shuka, N., Chettibi, M., Hayrapetyan, H., Pavo, N., Islamli, A., Pouleur, A.-C., Kusljugic, Z., Tokmakova, M., Milicic, D., Christodoulides, T., Malek, F., Køber, L., Koriem, M. A. G., Põder, P., Lassus, J., Roubille, F., Agladze, V., Frantz, S., Stavrati, A., Kosztin, A., Ingimarsdóttir, I. J., Campbell, P., Hasin, T., Oliva, F., Aidargaliyeva, N., Bajraktari, G., Mirrakhimov, E., Kamzola, G., El Neihoum, A. M., Zaliaduonyte, D., Moore, A., Vataman, E., Boskovic, A., Alami, M., Manintveld, O., Kostovska, E. S., Broch, K., Nessler, J., Franco, F., Popescu, B. A., Foscoli, M., Milosavljevic, A. S., Goncalvesova, E., Fras, Z., Gonzalez-Costello, J., Lindmark, K., Paul, M., Oudeh, A., Zakhama, L., Celik, A., Voronkov, L., Clark, A., Abdullaev, T., Prescott, E., James, S., Arbelo, E., Baigent, C., Borger, M. A., Buccheri, S., Ibanez, B., Køber, L., Koskinas, K. C., McEvoy, J. W., Mihaylova, B., Mindham, R., Neubeck, L., Nielsen, J. C., Pasquet, A. A., Rakisheva, A., Rocca, B., Rossello, X., Vaartjes, I., Vrints, C., Witkowski, A., & Zeppenfeld, K.
Affiliations
  • (Chairperson) ( )
  • (Task Force Co-ordinator) ( )
  • (United Kingdom)
  • (Germany)
  • (Switzerland)
  • (United States of America)
  • (Lithuania)
  • (Romania)
  • (Spain)
  • (Greece)
  • (France)
  • (Netherlands)
  • (Sweden)
  • (Poland)
  • (Slovenia)
  • (Singapore)
  • (Italy)
  • (Denmark)
ORCID
Venue
European Heart Journal
Publisher
Oxford University Press (OUP)
Published
2023-08-25
Volume
44
Issue
37
Pages
3627-3639
ISSN
  • 0195-668X
  • 1522-9645
DOI
10.1093/eurheartj/ehad195
Cited by
2,612
References
16
Language
en
Licence
academic.oup.com/pages/standard-publication-reuse-rights (vor)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review